HLS Therapeutics (TSX:HLS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.10) by 70 percent. This is a 66.67 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $14.673 million which beat the analyst consensus estimate of $14.467 million by 1.43 percent. This is a 3.54 percent increase over sales of $14.171 million the same period last year.